BridgeBio Pharma BBIO Finite Lived Intangible Assets Amortization Expense After Year Five
Finite Lived Intangible Assets Amortization Expense After Year Five at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's finite lived intangible assets amortization expense after year five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's finite lived intangible assets amortization expense after year five?
- BridgeBio Pharma (BBIO) reported finite lived intangible assets amortization expense after year five of $10.7M in Q1 2026.